Watkins V S, Smietana M, Conforti P M, Sides G D, Huck W
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Antimicrob Agents Chemother. 1997 Jan;41(1):72-5. doi: 10.1128/AAC.41.1.72.
In the treatment of group A beta-hemolytic streptococcal pharyngitis, penicillin is the drug of choice and erythromycin is the alternative. In a double-blind, randomized study, dirithromycin, a new macrolide, was compared with penicillin for the treatment of streptococcal pharyngitis. Of 121 patients who were treated with dirithromycin, 96.7% manifested a favorable clinical response, and of 136 patients treated with penicillin, 94.2% manifested a favorable clinical response. Streptococci were eradicated from the pharynges of 85.3% of 116 dirithromycin-treated patients and 82.5% of 126 penicillin-treated patients who returned for follow-up. There were no statistically significant differences in efficacy between the two groups. The incidence of abdominal symptoms was higher in dirithromycin-treated patients. Being as efficacious as penicillin and having the advantages over erythromycin of once-daily dosing and the lack of drug interactions, dirithromycin is an alternative to penicillin in the treatment of streptococcal pharyngitis for patients 12 years of age and older.
在治疗A组β溶血性链球菌性咽炎时，青霉素是首选药物，红霉素是替代药物。在一项双盲随机研究中，将新型大环内酯类药物地红霉素与青霉素用于治疗链球菌性咽炎进行了比较。在接受地红霉素治疗的121例患者中，96.7%表现出良好的临床反应；在接受青霉素治疗的136例患者中，94.2%表现出良好的临床反应。在116例接受地红霉素治疗且回来接受随访的患者中，85.3%的患者咽部链球菌被清除；在126例接受青霉素治疗且回来接受随访的患者中，82.5%的患者咽部链球菌被清除。两组之间的疗效无统计学显著差异。地红霉素治疗的患者腹部症状发生率较高。地红霉素与青霉素疗效相当，且具有优于红霉素的每日一次给药以及无药物相互作用的优点，对于12岁及以上的患者，地红霉素是治疗链球菌性咽炎时青霉素的替代药物。
